Not Yet RecruitingPhase 4ACTRN12609000886280
An observational case series of the use of anti-Immunoglobulin E antibody for the management of treatment-resistant systemic mastocytosis.
Sponsor
Dr Karl Bleasel
Enrollment
15 participants
Start Date
Nov 1, 2009
Study Type
Interventional
Conditions
Summary
The primary purpose of the study is to observe the effect of anti-immunoglobulin E antibody in the treatment of a small number of people with symptomatic mastocytosis.
Eligibility
Sex: Both males and femalesMin Age: 18 Yearss
Inclusion Criteria1
- Adults with symptomatic systemic mastocytosis that is resistant to other conventional therapies
Exclusion Criteria2
- Associated haematological clonal non-mast cell lineage disease or mast cell leukaemia;
- Pregnancy.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Anti-immunoglobulin E antibody will be administered to participants as a subcutaneous injection, at a dose of 375mg (which may be altered during the course of treatment, depending on individual patien
Anti-immunoglobulin E antibody will be administered to participants as a subcutaneous injection, at a dose of 375mg (which may be altered during the course of treatment, depending on individual patient response), every fortnight, for a total of 24 weeks, equivalent to twelve doses.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12609000886280
Related Trials
Study of Factors Regulating Mast Cell Proliferation
NCT000441221 location
Institutional Registry of Rare Diseases
NCT065737231 location
Analysis of the Role of IgE Proteoforms in Health and Disease
NCT073281781 location
Myeloproliferative Neoplasms (MPNs) Patient Registry
NCT027602381 location
Mastocytosis Registry (of Zurich)
NCT064668891 location